Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
BOSTON, March 07, 2022 – Radius Health, Inc. (NASDAQ: RDUS) announced that CEO Kelly Martin will join a virtual fireside chat hosted by Wells Fargo's Mohit Bansal on March 11, 2022, at 11:00am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, March 07, 2022 – Radius Health, Inc. (NASDAQ: RDUS) announced that CEO Kelly Martin will join a virtual fireside chat hosted by Wells Fargo's Mohit Bansal on March 11, 2022, at 11:00am ET. The event will be accessible via a live webcast on the company's investor relations website.
Radius is a biopharmaceutical company focused on bone health, orphan diseases, and oncology, with its lead product, TYMLOS® (abaloparatide), approved for treating postmenopausal women at high risk for osteoporosis-related fractures.
Details
News Market Reaction – RDUS
The recorded move for RDUS in the trading session of this news was -1.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a virtual fireside chat hosted by Mohit Bansal, Managing Director of Equity Research at Wells Fargo. The event will take place on Friday, March 11, 2022 at 11:00am ET.
A live webcast can be accessed on the investor relations section of the Company’s website, www.radiuspharm.com.
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.
Investor & Media Relations Contact:
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.